Hoenigl, Martin http://orcid.org/0000-0002-1653-2824
Enoch, David A.
Wichmann, Dominic
Wyncoll, Duncan
Cortegiani, Andrea
Funding for this research was provided by:
Gilead Sciences Europe Ltd
Medical University of Graz
Article History
Received: 16 August 2023
Accepted: 12 April 2024
First Online: 5 May 2024
Declarations
:
: MH received research funding and/or speaker and consultancy fees from Gilead, Astellas, MSD, Euroimmune, IMMY, Pulmocide, Mundipharma, Scynexis, F2G, and Pfizer. DAE received fees for lectures and consultancy from Tillots and Gilead. DW reports consultant and lecture fees from 3 M, Advants, AMEOS, Eumedica, EUSA, Gilead, InfectoPharm, Kite, Lilly, MSD, Novartis, Pfizer, and Shionogi. DWy has received speaker and consultancy fees from Gilead and Shionogi. AC received fees for lectures or consultancy by Gilead, MSD, Mundipharma, and Pfizer.
: A statement of consent was included at the start of the survey and consent was implied by completion and submission of the survey. Consent was therefore sought from the participating HCPs.
: Participants were informed that the aim was to publish aggregated data from the survey in a peer-reviewed journal. A statement of consent was included at the start of the survey and consent was implied by completion and submission of the survey.